Thomasville National Bank Purchases 21,868 Shares of Kenvue Inc. (NYSE:KVUE)

Thomasville National Bank increased its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 3.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 741,597 shares of the company's stock after purchasing an additional 21,868 shares during the quarter. Kenvue comprises about 1.3% of Thomasville National Bank's portfolio, making the stock its 28th biggest holding. Thomasville National Bank's holdings in Kenvue were worth $17,783,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of KVUE. Norges Bank bought a new stake in shares of Kenvue in the 4th quarter worth $521,348,000. Starboard Value LP bought a new stake in Kenvue in the fourth quarter worth about $467,864,000. Franklin Resources Inc. lifted its holdings in Kenvue by 61.5% in the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock valued at $912,059,000 after acquiring an additional 16,269,721 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock valued at $2,085,070,000 after purchasing an additional 10,682,003 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Kenvue by 3.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock worth $5,249,665,000 after purchasing an additional 8,211,748 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Kenvue Stock Down 2.7%

Shares of KVUE stock traded down $0.60 on Friday, hitting $21.44. The company's stock had a trading volume of 37,242,399 shares, compared to its average volume of 16,489,867. The stock has a market capitalization of $41.14 billion, a price-to-earnings ratio of 40.46, a P/E/G ratio of 2.62 and a beta of 0.98. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $25.17. The firm's fifty day moving average price is $23.03 and its 200-day moving average price is $22.49. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. The company had revenue of $3.74 billion during the quarter, compared to analysts' expectations of $3.69 billion. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The business's quarterly revenue was down 3.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.28 earnings per share. Research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were issued a dividend of $0.205 per share. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.82%. Kenvue's dividend payout ratio (DPR) is presently 149.09%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of a number of research reports. Canaccord Genuity Group raised their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Evercore ISI began coverage on Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price on the stock. Redburn Atlantic initiated coverage on Kenvue in a research note on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price target on the stock. Citigroup upped their price objective on shares of Kenvue from $22.00 to $24.50 and gave the company a "neutral" rating in a research note on Friday, May 9th. Finally, UBS Group raised their price objective on shares of Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Friday, May 9th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.